PALVELLA THERAPEUTICS

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

30 6月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

23 6月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

18 6月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

09 6月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

27 5月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

15 5月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

08 5月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

05 5月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

23 4月 2025 13:15:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

22 4月 2025 04:29:59 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

11 4月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

04 4月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

02 4月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

31 3月 2025 04:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

18 3月 2025 05:30:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

25 2月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

10 2月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

10 1月 2025 05:00:00 条件 Nasdaq GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

08 1月 2025 05:00:01 条件 Nasdaq GlobeNewswire